Hikma Pharmaceuticals (LON:HIK) Stock Price Expected to Rise, Berenberg Bank Analyst Says

Hikma Pharmaceuticals (LON:HIK) had its price target upped by equities research analysts at Berenberg Bank from GBX 2,400 ($29.81) to GBX 2,560 ($31.79) in a report released on Wednesday, MarketBeat.com reports. The brokerage currently has a “buy” rating on the stock. Berenberg Bank’s price objective would indicate a potential upside of 12.28% from the company’s previous close.

Hikma Pharmaceuticals Stock Performance

Shares of HIK stock opened at GBX 2,280 ($28.32) on Wednesday. The company has a market capitalization of £5.06 billion, a P/E ratio of 3,507.69, a PEG ratio of 2.38 and a beta of 0.41. Hikma Pharmaceuticals has a fifty-two week low of GBX 1,750 ($21.73) and a fifty-two week high of GBX 2,290 ($28.44). The company has a debt-to-equity ratio of 55.48, a quick ratio of 1.27 and a current ratio of 1.66. The stock has a 50 day moving average price of GBX 2,001.97 and a two-hundred day moving average price of GBX 1,947.80.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.